Tesamorelin research: what the published studies show

Liver Fat

A 2019 randomized, double-blind, multicenter trial enrolled 61 people with HIV and a hepatic fat fraction of 5% or more.^[1] Thirty received tesamorelin 2 mg daily and 30 received identical placebo for 12 months, followed by a six-month open phase.^[1]

Hepatic fat fraction fell further on tesamorelin than on placebo, with an absolute effect size of minus 4.1% and a relative reduction of 37% from baseline.^[1] After 12 months, 35% of the tesamorelin group and 4% of the placebo group had a hepatic fat fraction below 5%.^[1] Changes in fasting glucose and glycated hemoglobin did not differ between groups at 12 months.^[1]

Localized injection site complaints were more common on tesamorelin, though none were judged serious.^[1] The authors' conclusion is that tesamorelin might be beneficial in this population, and that further studies are needed on long-term effects.^[1] Both hedges are theirs.^[1]

Visceral Fat

A 2014 randomized trial gave tesamorelin or placebo to 48 patients with HIV and abdominal fat accumulation for six months.^[2] Visceral adipose tissue fell by a mean of 34 square centimetres on tesamorelin and rose by 8 on placebo, a treatment effect of minus 42 square centimetres.^[2] Liver fat, measured as lipid-to-water percentage, fell by a median of 2.0% against a rise of 0.9% on placebo.^[2]

Fasting glucose rose in the tesamorelin group at two weeks, by a mean of 9 mg/dL against 2 mg/dL on placebo, a treatment effect of 7 mg/dL.^[2] That difference did not persist: changes in fasting glucose at six months and in two-hour glucose were not significant across time points.^[2] The transient rise is reported here because it is in the source and because it is the kind of detail a page that only listed the fat outcomes would drop.^[2]

Neurocognition

A 2025 six-month randomized open-label phase 2 trial enrolled 73 virally suppressed people with HIV and abdominal obesity, allocated 3:2 to tesamorelin 2 mg daily or standard of care.^[3] The primary outcome was change in neurocognitive performance at six months.^[3]The tesamorelin group showed a trend toward improvement that did not reach significance on its own, and the standard-of-care group did not.^[3] The between-group difference was not significant.^[3] IGF-1 rose, but the change did not correlate with the cognitive score or with waist circumference.^[3] Waist circumference fell more on tesamorelin, by a median difference of 2.7 cm.^[3]

The authors' conclusion states that tesamorelin reduced waist circumference while the cognitive benefit was not demonstrated.^[3] This trial is on the page because a product page that carried only the two positive trials would be selecting from a record of three.^[2]

The Class in Human Studies

A 2018 review of growth hormone secretagogues states that few long-term, rigorously controlled studies have examined their efficacy and safety.^[4] It reports the class as well tolerated, with some concern for increases in blood glucose because of decreases in insulin sensitivity.^[4] That concern is visible in reference 2's two-week glucose signal.^[2] The review closes by saying long-term safety, including cancer incidence and mortality, still needs evaluation.^[4]

A 2026 narrative review of peptides in sports medicine distinguishes compounds that have been through formal development from a parallel market of compounds that have not, where rigorous human safety data are scarce.^[5]Tesamorelin is placed in the former group.^[5]

State of the Evidence

Three things shape this page, and the first is that the evidence is unusually strong for this catalog.

Three randomized controlled trials in people support it, from two independent groups.^[1] Two are positive on their primary outcome and one is not.^[3] All three used the compound named unambiguously, with no fragment or conjugate ambiguity.^[2]

The second is the population. Every trial here enrolled people with HIV, most with abdominal fat accumulation.^[1] Nothing in this set establishes what the compound does in anyone else, and the licensed indication is correspondingly narrow.^[5]

The third is the glucose signal. Reference 2 reports a significant rise in fasting glucose at two weeks that did not persist to six months.^[2] Reference 1 reports no difference in fasting glucose or glycated hemoglobin at 12 months.^[1] The class review names insulin sensitivity as the open safety question for secretagogues generally.^[4] Those three statements are compatible, and the page reports all three rather than the most comfortable one.